Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses

Full text
Author(s):
Marques Rossetti, Renata Ariza [1] ; Cristina Lorenzi, Noely Paula [2] ; Yokochi, Kaori [2] ; Sartor de Faria Rosa, Maria Beatriz [3] ; Benevides, Luciana [4] ; Ramos Margarido, Paulo Francisco [2] ; Baracat, Edmund Chada [3, 2] ; Carvalho, Jesus Paula [3] ; Villa, Luisa Lina [3, 5] ; Lepique, Ana Paula [1]
Total Authors: 10
Affiliation:
[1] Univ Sao Paulo, Inst Ciencias Biomed, Dept Immunol, Sao Paulo - Brazil
[2] Univ Sao Paulo, Hosp Univ, Sao Paulo - Brazil
[3] Univ Sao Paulo, Fac Med, Inst Canc Estado Sao Paulo, Sao Paulo - Brazil
[4] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Immunol & Biochem, Ribeirao Preto - Brazil
[5] Univ Sao Paulo, Fac Med, Inst Radiol, Sao Paulo - Brazil
Total Affiliations: 5
Document type: Journal article
Source: PLoS One; v. 13, n. 7 JUL 5 2018.
Web of Science Citations: 5
Abstract

Immune evasion by tumors includes several different mechanisms, including the inefficiency of antigen presenting cells (APCs) to trigger anti-tumor T cell responses. B lymphocytes may display a pro-tumoral role but can also be modulated to function as antigen presenting cells to T lymphocytes, capable of triggering anti-cancer immune responses. While dendritic cells, DCs, are the best APC population to activate naive T cells, DCs or their precursors, monocytes, are frequently modulated by tumors, displaying a tolerogenic phenotype in cancer patients. In patients with cervical cancer, we observed that monocyte derived DCs are tolerogenic, inhibiting allogeneic T cell activation compared to the same population obtained from patients with precursor lesions or cervicitis. In this work, we show that B lymphocytes from cervical cancer patients respond to treatment with sCD40L and IL-4 by increasing the CD80(+)CD86(+) population, therefore potentially increasing their ability to activate T cells. To test if B lymphocytes could actually trigger anti-tumor T cell responses, we designed an experimental model where we harvested T and B lymphocytes, or dendritic cells, from tumor bearing donors, and after APC stimulation, transplanted them, together with T cells into RAG1(-/-) recipients, previously injected with tumor cells. We were able to show that anti-CD40 activated B lymphocytes could trigger secondary T cell responses, dependent on MHC-II expression. Moreover, we showed that dendritic cells were resistant to the anti-CD40 treatment and unable to stimulate anti-tumor responses. In summary, our results suggest that B lymphocytes may be used as a tool for immunotherapy against cancer. (AU)

FAPESP's process: 11/11121-8 - Study of signaling pathways triggered by and biological effects of CD40 in cervical tumors.
Grantee:Renata Ariza Marques Rossetti
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 14/19326-6 - Tumor microenvironment, inflammation and immunomodulation: therapeutic possibilities and prognostic markers
Grantee:Ana Paula Lepique
Support Opportunities: Regular Research Grants
FAPESP's process: 10/20010-2 - Immune response modulation by tumor cells
Grantee:Ana Paula Lepique
Support Opportunities: Regular Research Grants